Literature DB >> 30726990

Combining immunofluorescence with immunoblot assay improves the specificity of autoantibody testing for myositis.

M Infantino1, M Tampoia2, M Fabris3, M G Alessio4, G Previtali4, G Pesce5, G Deleonardi6, B Porcelli7, M Musso8, V Grossi1, M Benucci9, M Manfredi1, N Bizzaro10.   

Abstract

OBJECTIVE: Immunoblot (IB) methods are widely used to detect myositis-specific autoantibodies (MSAs); however, false-positive results are common. In this study, we aimed to determine whether associating the anti-nuclear antibody (ANA) IIF pattern may help to improve the specificity of MSA detection by IB in patients with idiopathic inflammatory myositis (IIM).
METHODS: Serum samples from 104 patients presenting with muscle weakness/myalgia and positive to at least one MSA by IB (MYOS12 Diver and MIOS7 Diver, D-tek) were tested for ANAs on HEp-2000 cells (Immuno Concepts). The chi-square test was used to analyse the concordance of the MSA result and its corresponding pattern by ANA testing between patients with and without IIM.
RESULTS: Eighty-three of the 104 patients had a diagnosis of definite IIM, while in 21 cases, patients were affected by other autoimmune diseases or various non-systemic diseases. Forty nine of 83 (59%) patients in the IIM group and 4/21 (19%) in the non-IIM group showed a concordance between ANA pattern and MSAs by IB (P < 0.001). MSA monopositivity was significantly associated with IIM (91.6%) compared with 61.9% in the non-IIM group (P = 0.0005).
CONCLUSIONS: Considering both the MSA result and its corresponding pattern by ANA testing may help to improve the specificity of MSA detection by IB and to confirm the diagnosis of MSA-associated IIM. The monopositivity of MSAs is an important additional tool to validate IB results.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ANA pattern; IIM; MSA; algorithm; antibody; combination; immunoblot; immunofluorescence; myositis; specificity

Mesh:

Substances:

Year:  2019        PMID: 30726990     DOI: 10.1093/rheumatology/key451

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  5 in total

1.  The use and diagnostic value of testing myositis-specific and myositis-associated autoantibodies by line immuno-assay: a retrospective study.

Authors:  Angelika Lackner; Viktoria Tiefenthaler; Jalia Mirzayeva; Florian Posch; Christopher Rossmann; Kastriot Kastrati; Helga Radner; Ulrike Demel; Judith Gretler; Michael Stotz; Winfried B Graninger; Martin H Stradner
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-08       Impact factor: 5.346

2.  Positioning of myositis-specific and associated autoantibody (MSA/MAA) testing in disease criteria and routine diagnostic work-up.

Authors:  Carolien Bonroy; Yves Piette; Yves Allenbach; Xavier Bossuyt; Jan Damoiseaux
Journal:  J Transl Autoimmun       Date:  2022-02-11

3.  An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations.

Authors:  Micaela Fredi; Ilaria Cavazzana; Angela Ceribelli; Lorenzo Cavagna; Simone Barsotti; Elena Bartoloni; Maurizio Benucci; Ludovico De Stefano; Andrea Doria; Giacomo Emmi; Martina Fabris; Marco Fornaro; Federica Furini; Maria Grazia Giudizi; Marcello Govoni; Anna Ghirardello; Luca Iaccarino; Fiorenzo Iannone; Maria Infantino; Natasa Isailovic; Maria Grazia Lazzaroni; Mariangela Manfredi; Alessandro Mathieu; Emiliano Marasco; Paola Migliorini; Carlomaurizio Montecucco; Boaz Palterer; Paola Parronchi; Matteo Piga; Federico Pratesi; Valeria Riccieri; Carlo Selmi; Marilina Tampoia; Alessandra Tripoli; Giovanni Zanframundo; Antonella Radice; Roberto Gerli; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-29       Impact factor: 10.817

4.  Myositis-specific Antibodies Identify A Distinct Interstitial Pneumonia with Autoimmune Features Phenotype.

Authors:  Julia Graham; Iazsmin Bauer Ventura; Chad A Newton; Cathryn Lee; Noelle Boctor; Janelle Vu Pugashetti; Claire Cutting; Elena Joerns; Habrinder Sandhu; Jonathan H Chung; Christine Kim Garcia; Michael Kadoch; Imre Noth; Ayodeji Adegunsoye; Mary E Strek; Justin M Oldham
Journal:  Eur Respir J       Date:  2020-07-16       Impact factor: 16.671

5.  Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes.

Authors:  Benoît Déchelotte; Sergio Muñiz-Castrillo; Bastien Joubert; Alberto Vogrig; Géraldine Picard; Véronique Rogemond; Anne-Laurie Pinto; Christine Lombard; Virginie Desestret; Nicole Fabien; Jérôme Honnorat
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-03-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.